Is Wegovy a SGLT2 Inhibitor, or Does It Work Differently?

What does Wegovy actually do in the body?

Semaglutide is a synthetic version of GLP-1, a hormone your gut releases after eating. It binds to GLP-1 receptors in the brain's appetite-regulating centres, slowing the feeling of hunger and making smaller amounts of food feel satisfying. It also slows the rate at which the stomach empties, which extends that sense of fullness further. None of this involves the kidneys or glucose filtration.

The semaglutide overview on our site covers the mechanism in more detail, but the short version is this: Wegovy changes the body's hunger signalling rather than its glucose-handling chemistry. That is why the main side effects are gastrointestinal (nausea, loose stools, constipation) rather than the urinary-tract symptoms more commonly associated with a semaglutide inhibitor and how it differs from GLP-1 medicines. The NHS semaglutide medicines page summarises the mechanism and common effects in clear terms if you want an independent overview.

In clinical trials, semaglutide 2.4mg produced an average body-weight reduction of around 15% over 68 weeks in adults with obesity, as reported in the STEP 1 study. That result comes from reduced calorie intake driven by appetite suppression, not from glucose being lost in urine.

So what exactly is an SGLT2 inhibitor, and how does it differ?

SGLT2 stands for sodium-glucose co-transporter 2, a protein in the kidneys that normally reclaims glucose from filtered blood back into circulation. SGLT2 inhibitors block this reabsorption, so more glucose passes out of the body in urine. The result is lower blood-sugar levels, and in some patients modest weight loss as calories are literally excreted.

Medicines in this class (empagliflozin (Jardiance), dapagliflozin (Forxiga) and canagliflozin (Invokana) are the most prescribed in the UK) are licensed primarily for type 2 diabetes and, in some cases, heart failure or chronic kidney disease. Their weight-loss effects are generally smaller than those seen with GLP-1 medicines and are a secondary benefit rather than the primary licensed indication.

The two classes work at completely different points in the body's physiology. You can see why they get conflated: both appear in discussions of metabolic health, both can lower blood sugar, and both are sometimes prescribed to people managing their weight alongside diabetes. But a clinician would distinguish them immediately. For a fuller comparison of how different Wegovy sits alongside other treatment options, our comparison pages walk through the evidence.

Can Wegovy and SGLT2 inhibitors be taken together?

This is one of the questions our prescribers hear regularly from people who are already on one medication and wondering about the other. The short answer is: sometimes yes, but it depends on your full clinical picture, and that decision rests with your prescriber, not a checklist online.

There is no blanket contraindication between semaglutide and SGLT2 inhibitors. In specialist diabetes and obesity medicine, the two are occasionally used together when a patient has both significant weight to lose and poorly controlled blood sugar, though that combination requires careful monitoring. For someone taking Wegovy, which is licensed specifically for weight management, who also happens to be on an SGLT2 inhibitor for heart failure, the overlap may be straightforward, or it may require a dose review. Your GP or prescriber needs the full picture: all current medicines, your kidney function, your blood-sugar history.

If you are wondering whether Wegovy might suit your situation, the right starting point is a proper consultation rather than an online comparison. Our eligibility guide outlines who Wegovy is licensed for and what a prescriber considers. A quick note on practicalities: if you order by midday on a weekday, our prescribers review consultations the same day, so you tend to have clarity before the afternoon is out.

Where does Wegovy sit within the UK landscape of weight-loss medicines?

Wegovy is one of two injectable GLP-1 medicines currently licensed in the UK for weight management, the other being Mounjaro (tirzepatide), which adds a second receptor pathway. How Wegovy compares as a GLP-1 medicine is worth reading if that distinction matters to you. As of summer 2026, there is also an oral semaglutide tablet (Wegovy tablets), approved by the MHRA in June 2026 as the first oral GLP-1 licensed for weight management in the UK.

NICE recommends semaglutide (Wegovy) under specific criteria, including BMI thresholds and weight-related comorbidities, and only within specialist weight management services for a maximum of two years on the NHS. NICE technology appraisal TA875 sets out those criteria in full. Private routes, like the clinical service at nume, do not require a referral, but the same clinical standards apply: a GPhC-registered prescriber reviews every consultation personally.

If you are trying to work out which medicine (or which class of medicine) fits your health history, starting a free consultation with our prescribers is the clearest way to get a considered answer.